A phase IIa , double-blind, placebo-controlled dose-ranging study of KHK4563

A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221534

Enrollment

100

Registered

2011-08-08

Start date

2011-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

investigational material(s) Generic name etc : KHK4563 INN of investigational material : Therapeutic category code : 225 Bronchodilators Dosage and Administration for Investigational material : Multi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Uncontrolled asthma requiring medium-dose or high-dose ICS plus LABA - History of => 2 but =< 6 documented asthma exacerbations in the 12 months that required use of a systemic corticosteroid burst

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Asthma exacerbation	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026